secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001193125-25-252207
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q3 revenue $394.2M, GAAP EPS $0.49; raises FY2025 guidance
-------------------------------------------------------------------

- Q3 total revenues $394.2M up 4% YoY; proprietary net sales $317.4M up 16% YoY.
- LYBALVI sales $98.2M (+32% YoY); ARISTADA $98.1M (+16% YoY); VIVITROL $121.1M (+7% YoY).
- GAAP net income $82.8M vs $92.4M in Q3 2024; diluted EPS $0.49.
- FY2025 revenue guidance raised to $1.43-1.49B from $1.34-1.43B; GAAP net income now $230-250M.
- CEO highlighted proposed Avadel acquisition and positive phase 2 data for alixorexton in narcolepsy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/0001193125-25-252207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/alks-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-252207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer